Capricor Therapeutics had its Relative Strength (RS) Rating upgraded from 87 to 91 Thursday.
Here Are 3 Keys For Successful Stock Investing
This exclusive rating from Investor's Business Daily tracks share price performance with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the trailing 52 weeks compares to all the other stocks in our database.
Over 100 years of market history reveals that the top-performing stocks tend to have an RS Rating of at least 80 in the early stages of their moves.
Capricor Therapeutics is now considered extended and out of buy range after clearing a 5.48 buy point in a first-stage cup without handle. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
The company showed 0% EPS growth in its most recent report. Revenue increased -100%.
Capricor Therapeutics earns the No. 177 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, Catalyst Pharmaceuticals and Eton Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
